Skip to main navigation Skip to search Skip to main content

Update on nephrogenic systemic fibrosis

  • P. Marckmann
  • , V.B. Logager
  • , Henrik S. Thomsen

    Research output: Contribution to journal › Journal article › Research › peer-review

    Abstract

    Gadolinium-based contrast agents were for many years considered safe, but this is no longer the case. The least stable agents may trigger the development of nephrogenic systemic fibrosis (NSF), a generalized fibrotic disorder, in renal failure patients. The use of gadodiamide and gadopentetate dimeglumine is now contraindicated in Europe and Japan in patients who have a glomerular filtration rate less than 30 mL/min/1.73 m(2), including those on dialysis. The fear of NSF, however, should not lead to an enhanced MR imaging examination being denied when there is a good clinical indication to give a gadolinium-based contrast agent
    Udgivelsesdato: 2008/11
    Original languageEnglish
    JournalMagnetic Resonance Imaging Clinics of North America
    Volume16
    Issue number4
    Pages (from-to)551-60, vii
    ISSN1064-9689
    Publication statusPublished - 2008

    Cite this